Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Rare instances of myopathy are associated with all statins, but cerivastatin was withdrawn from clinical use due to a greater incidence of myopathy. The mechanism of statin-induced myopathy with respect to tissue disposition was investigated by measuring the systemic, hepatic, and skeletal muscle exposure of cerivastatin, rosuvastatin, and simvastatin in rats before and after muscle damage. The development of myopathy was not associated with the accumulation of statins in skeletal muscle. For each statin exposure was equivalent in muscles irrespective of their fibre-type sensitivity to myopathy. The low amount of each statin in skeletal muscle relative to the liver does not support a significant role for transporters in the disposition of statins in skeletal muscle. Finally, the concentration of cerivastatin necessary to cause necrosis in skeletal muscle was considerably lower than rosuvastatin or simvastatin, supporting the concept cerivastatin is intrinsically more myotoxic than other statins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, progress has been hampered by the fact that myopathy has been difficult to induce with statin treatment in preclinical models.100–103”
From Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) · cites this paper as [101]
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Drug Metabolism and Disposition
(2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12259_4 · Cited by 2,515
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 3×
“The risk of myopathy with the currently prescribed statins is generally low, although this increases with concomitant administration of agents such as cyclosporine and gemfibrizol which increase plasma drug exposure (Omar et al. 2001; Hodel 2002; Rosenson 2004; Graham et al. 2004).”
BackgroundDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Research works printed but not linked: 2
- Home Office, 1986, Guidance on the Operations of the Animals (Scientific Procedures) Act 1986
- Omar MA, 2001, Annals of Pharmacotherapy, 35, 1096, 10.1345/aph.10228 · doi:10.1345/aph.10228 · Paper page
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
What is a relevant statin concentration in cell experiments claiming pleiotropic effects?
Björkhem‐Bergman, L., Lindh, J. D., & Bergman, P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03907.x · Cited by 207
Sathasivam, S. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.01.004 · Cited by 165
A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy
Whitehead, N. P., Kim, M. J., Bible, K. L., Adams, M. E., & Froehner, S. C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509536112 · Cited by 110
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 84
Metadata
- Authors
- Sidaway, J., Wang, Y., Marsden, A. M., Orton, T. C., Westwood, F. R., Azuma, C. T., & Scott, R. C.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Corresponding author
- Sidaway, J.
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 39
- Issue
- 1
- Pages
- 90-98
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W2098417114
- Cited by
- 28
- References
- 47
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2021: 3 · 2019: 3 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 1 · 2012: 6
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Xenobiotica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- statin-induced myopathy, cerivastatin, rosuvastatin, simvastatin, tissue disposition, muscle fiber type, muscle necrosis, myotoxicity, drug safety
- MeSH terms
- Rosuvastatin Calcium, Animals, Disease Models, Animal, Female, Fluorobenzenes, Liver, Muscular Diseases, Pyridines, Pyrimidines, Sulfonamides, Rats, Wistar, Muscle, Skeletal, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. https://app.cochat.ai/papers/10.1080/00498250802585539
- The paper
- Sidaway, J., Wang, Y., Marsden, A. M., Orton, T. C., Westwood, F. R., Azuma, C. T., & Scott, R. C. (2009). Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica. https://doi.org/10.1080/00498250802585539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.